Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
29 hedge funds and large institutions have $58.8M invested in Sinovac Biotech, Ltd in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 5 closing their positions.
4% more capital invested
Capital invested by funds: $56.7M → $58.8M (+$2.06M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 31 → 29 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$883K |
| 2 |
State Street
Boston,
Massachusetts
|
+$395K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$248K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$94.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$62.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$551K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$544K |
| 3 |
Renaissance Technologies
New York
|
-$395K |
| 4 |
Two Sigma Investments
New York
|
-$282K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$215K |
SVA Hedge Fund Activity: Q1 2018 in Review
29 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2018, worth a combined $58.8M — up 3.6% from $56.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SVA and 4 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 6 added.
The largest buyer was Invesco, opening a new position worth an estimated $883K. The largest seller was Deutsche Bank, cutting an estimated $551K.
- 29 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2018, down from 31 in Q4 2017.
- Funds reported $58.8M of Sinovac Biotech, Ltd stock for Q1 2018, up 3.6% quarter-over-quarter.
- 4 funds opened new Sinovac Biotech, Ltd positions in Q1 2018 and 5 closed out, a net change of -1 holder.
- The largest Sinovac Biotech, Ltd buyer in Q1 2018 was Invesco, an estimated $883K added.
- The largest Sinovac Biotech, Ltd seller in Q1 2018 was Deutsche Bank, an estimated $551K sold.
Based on aggregated 13F filings for Q1 2018.